CA2639336A1 - Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease - Google Patents
Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease Download PDFInfo
- Publication number
- CA2639336A1 CA2639336A1 CA002639336A CA2639336A CA2639336A1 CA 2639336 A1 CA2639336 A1 CA 2639336A1 CA 002639336 A CA002639336 A CA 002639336A CA 2639336 A CA2639336 A CA 2639336A CA 2639336 A1 CA2639336 A1 CA 2639336A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitors
- histone deacetylase
- agent
- hdac
- agent comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 21
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 13
- 230000006872 improvement Effects 0.000 title description 7
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 162
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 162
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 146
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 62
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims abstract description 15
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims abstract description 15
- 239000003446 ligand Substances 0.000 claims abstract description 13
- 238000011262 co‐therapy Methods 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims description 50
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 48
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 21
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 20
- 229940036555 thyroid hormone Drugs 0.000 claims description 17
- 239000005495 thyroid hormone Substances 0.000 claims description 17
- 230000002861 ventricular Effects 0.000 claims description 9
- 230000001771 impaired effect Effects 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 229940035722 triiodothyronine Drugs 0.000 claims description 5
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims description 4
- 102100039385 Histone deacetylase 11 Human genes 0.000 claims description 4
- 102100038720 Histone deacetylase 9 Human genes 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 102100039999 Histone deacetylase 2 Human genes 0.000 claims description 3
- 102100021455 Histone deacetylase 3 Human genes 0.000 claims description 3
- 102100021454 Histone deacetylase 4 Human genes 0.000 claims description 3
- 102100021453 Histone deacetylase 5 Human genes 0.000 claims description 3
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims description 3
- 102100038715 Histone deacetylase 8 Human genes 0.000 claims description 3
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 claims description 3
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 208000005333 pulmonary edema Diseases 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 2
- 208000000059 Dyspnea Diseases 0.000 claims description 2
- 206010013975 Dyspnoeas Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 230000009787 cardiac fibrosis Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 208000013220 shortness of breath Diseases 0.000 claims description 2
- 108010024124 Histone Deacetylase 1 Proteins 0.000 claims 2
- 108010023981 Histone Deacetylase 2 Proteins 0.000 claims 2
- 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 2
- 108700038332 Histone deacetylase 11 Proteins 0.000 claims 2
- 101710177324 Histone deacetylase 4 Proteins 0.000 claims 2
- 108050004676 Histone deacetylase 5 Proteins 0.000 claims 2
- 102100038719 Histone deacetylase 7 Human genes 0.000 claims 2
- 101710177330 Histone deacetylase 7 Proteins 0.000 claims 2
- 101710177327 Histone deacetylase 8 Proteins 0.000 claims 2
- 101710177326 Histone deacetylase 9 Proteins 0.000 claims 2
- 101710107444 Polyamine deacetylase HDAC10 Proteins 0.000 claims 2
- 108010074724 histone deacetylase 3 Proteins 0.000 claims 2
- 230000001965 increasing effect Effects 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 10
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- -1 aniline amide Chemical class 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000003893 Histone acetyltransferases Human genes 0.000 description 3
- 108090000246 Histone acetyltransferases Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 108090000721 thyroid hormone receptors Proteins 0.000 description 3
- 102000004217 thyroid hormone receptors Human genes 0.000 description 3
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091005772 HDAC11 Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical compound C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WONYMNWUJVKVII-UHFFFAOYSA-N 3,5-diiodothyropropionic acid Chemical compound IC1=CC(CCC(=O)O)=CC(I)=C1OC1=CC=C(O)C=C1 WONYMNWUJVKVII-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000736355 Euthyroides Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 1
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 1
- 101001032113 Homo sapiens Histone deacetylase 7 Proteins 0.000 description 1
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 1
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 description 1
- 101001035694 Homo sapiens Polyamine deacetylase HDAC10 Proteins 0.000 description 1
- 101000802091 Homo sapiens Thyroid hormone-inducible hepatic protein Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- QNAZTOHXCZPOSA-UHFFFAOYSA-N Sobetirome Chemical compound C1=C(O)C(C(C)C)=CC(CC=2C(=CC(OCC(O)=O)=CC=2C)C)=C1 QNAZTOHXCZPOSA-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000010117 myocardial relaxation Effects 0.000 description 1
- MUTBJZVSRNUIHA-UHFFFAOYSA-N n-hydroxy-2-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 MUTBJZVSRNUIHA-UHFFFAOYSA-N 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 108091008757 nuclear thyroid hormone receptors Proteins 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A therapeutic combination, useful in a co-therapy method for improving cardiovascular performance and/or treating cardiovascular diseases, is provided comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand.
Description
THERAPEUTIC COMBINATIONS AND METHODS FOR CARDIOVASCULAR
IMPROVEMENT AND TREATING CARDIOVASCULAR DISEASE
FIELD OF THE INVENTION
[0001i The present invention generally relates to therapeutic combinations and methods useful for improving cardiovascular performance and treating cardiovascular disease.
BACKGROUND OF THE INVENTION
10002] Histone deacetylases ("HDACs") are histone acetyltransferases which transfer an acetyl group to histones thereby playing a role in regulation of gene expression. At present, there are eleven known vertebrate HDACs: HDAC1 through HDAC11. HDAC1, HDAC2, HDAC3, HDAC8, and HDAC11 are class I HDACs. The class I HDACs are ubiquitously expressed, predominantly nuclear, and are believed to function mainly as transcriptional co-repressors. HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10 are class II HDACs. The class II HDACs are tissue specific, suggesting that they may have distinct functions in cellular differentiation and developmental processes. A variety of HDAC inhibitors have been identified.
See, for example, Moradeli et al., Histone Deacetylase Inhibitors: Latest Developments, Trends, and Prospects, CURR MED CHEM: ANTI-CANCER AGENTS 5(5):529-560 (2005).
[0003] Nuclear hormone receptors are ligand-activated transcription factors that regulate gene expression by interacting with specific DNA sequences upstream of their target genes. As early as 1968 a two-step mechanism of action was proposed for these receptors based upon the observation of an inactive and an active state of the receptors.
The first step involves activation through binding of the hormone; the second step consists of receptor binding to DNA and regulation of transcription.
[0004] By interacting with their nuclear receptors, hormones regulate a wide variety of physiological functions including metabolism, growth, and cell differentiation. Because disruptions in these functions often cause disease, the study of nuclear hormone receptors and the hormones which bind them are a rapidly developing area of research.
[0005] Thyroid cells produce the thyroid hormones, thyroxine ("T4") and triiodothyronine (73"). Thyroid hormones exert effects on the heart and the cardiovascular system. T3 has been shown to act on the cardiac myocyte via genomic (nuclear) and nongenomic pathways. T3 binds to nuclear thyroid hormone receptors ("TRs") which in turn bind to thyroid hormone response elements in the promoter region of thyroid hormone-responsive genes. In the presence of T3, TRs activate transcription by recruiting coactivator complexes, and in the absence of T3, TRs repress transcription by recruiting corepressor complexes.
100061 The prevalence of cardiovascular diseases, conditions, and adverse effects is increasing in the patient population. Therefore, there is a need for drug therapies useful for improving cardiovascular performance, and treating cardiovascular disease.
[0007] US 6,544,957 identifies the compound 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinofin-2-yl)-hexanoic acid hydroxyamide, termed "scriptaid" as a histone deacetylase inhibitor, and then mentions a composition containing scriptaid and an expression construct encoding a therapeutic polypeptide to increase production of a polypeptide. However, the patent discloses neither a combination of an HDAC
inhibitor and thyroid hormone, nor a use of any combination of agents treating cardiovascular diseases.
[0008] Thyroid hormone (TH) is known to be involved in histone modification.
More specifically, Alan P. Wolffe, Nature (News and Views) Vol. 287, 16-17 (1997), mentions that the presence of TH helps recruitment of histone acetyltransferases to relieve transcriptional repression. However, this publication does not teach a combination comprising a HDAC inhibitor and a thyroid hormone to treat cardiovascular disease.
100091 Mitchell A. Lazar, J. Clin. Invest. 112:497-499 (2003) mentions that TH
induces binding of transcriptional coactivators possessing histone acetyltransferase activity. However, this publication does not teach a combination comprising a HDAC
inhibitor and a thyroid hormone to treat cardiovascular disease.
SUMMARY OF THE INVENTION
100101 There is now provided, a therapeutic combination comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand, and the second agent is present in a sub-optimal dose.
[0011] There is further provided, a co-therapy method for improving cardiovascular performance, comprising administering to an animal a first amount of a first agent comprising a histone deacetylase inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
[0012] There is still further provided, a co-therapy method for treating cardiovascular disease, comprising administering to an animal a first amount of a first agent comprising a histone deacetylase inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Fig. 1 is a graphical representation of the results obtained from the study described in the Example herein.
[0014] Fig. 2 is a graphical representation of the results obtained from the study described in the Example herein.
DETAILED DESCRIPTION OF THE INVENTION
[0015] This detailed description is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This description and its specific examples are intended for purposes of illustration only. This invention, therefore, is not limited to the embodiments described in this patent application, and may be variously modified.
[0016] In various aspects of the invention, a therapeutic combination and method is provided for improving cardiovascular performance, and preventing and/or treating cardiovascular disease.
100171 The methods of this invention are particularly suitable for use with humans, but may be used with other animals, particularly mammals, such as, for example, non-human primates (e.g., monkeys, chimpanzees, etc.), companion animals (e.g., dogs, cats, horses, etc.), farm animals (e.g., goats, sheep, pigs, cattle, etc.), laboratory animals (e.g., mice, rats, etc.), and wild and zoo animals (e.g., wolves, bears, deer, etc.).
[0018] Cardiovascular performance may be improved in a number of ways. For example, cardiovascular performance is improved by preventing and/or alleviating any cardiovascular-associated condition or symptom. Preventing in this context means reducing the risk of, delaying the onset of, and/or keeping a subject from developing the cardiovascular disease state, condition, or symptom thereof.
[0019] Cardiovascular performance may also be improved by enhancing the cardiovascular fitness of healthy subjects. Examples of cardiovascular improvement include, but are not limited to, increasing a maximum rate of oxygen consumption (VO2max), increasing partial pressure of oxygen (P02), and increasing exercise time.
[0020] Improvement of cardiovascular performance further includes the reduction or elimination of risks or adverse events associated with any cardiovascular treatment or regime.
[0021] Further exemplary improvements of cardiovascular performance include the reduction or alleviation of one or more of the following cardiovascular-associated conditions, symptoms, or adverse events: decreased exercise capacity, severe recurrent headache, decreased blood ejection volume, increased left ventricular end diastolic pressure, increased pulmonary capillary wedge pressure, decreased cardiac output, low cardiac index, increased pulmonary artery pressures, increased left ventricular end systolic and diastolic dimensions, increased left and right ventricular wall stress, increased wall tension, decreased quality of life, disease-related morbidity and mortality, confusion and fatigue, chest pain, dypsnea, irregular heartbeat, and blood in the urine.
[0022] Improvement of cardiovascular performance can be measured in variety of ways known to those skilled in the art. Exemplary methods to measure improvement of cardiovascular performance include, but are not limited to, echocardiogram, electrocardiogram, 6-minute walk test, cardiac index, cardiac output, LVEDP
(left ventricular end diastolic pressure), ejection fraction, PAP (pulmonary arterial pressure), and echo based measurements including cardiac dimension, ventricular filling velocity via Doppler (mitral velocity), decreased dypsnea and pulmonary edema.
[0023] Further, the present invention can be used to treat or alleviate cardiovascular disease states. Treating includes ameliorating and/or eradicating the cardiovascular disease state, condition, or symptom thereof.
[0024] Exemplary cardiovascular disease states or conditions which may be improved include, but are not limited to diastolic heart failure, diastolic dysfunction, cardiac fibrosis, hypertrophy, impaired ventricular relaxation, impaired ventricular filling, pulmonary hypertension, pulmonary edema, shortness of breath, hypertension of all etiologies, acute coronary syndrome (including unstable angina and non-Q wave infarction), myocardial infarction, heart failure, systolic heart failure, stroke, occlusive stroke, hemorrhagic stroke and combinations thereof.
[0025] The term "therapeutic combination" refers to a plurality of agents that, when administered to a subject together or separately, are co-active in bringing therapeutic benefit to the subject. Such administration is referred to as "combination therapy," "co-therapy," "adjunctive therapy" or "add-on therapy." For example, one agent can potentiate or enhance the therapeutic effect of another (i.e. provide a synergistic effect), or reduce an adverse side effect of another, or one or more agents can be effectively administered at a lower dose than when used alone, or can provide greater therapeutic benefit than when used alone, or can complementarily address different aspects, symptoms or etiological factors of a disease or condition.
[0026] As such, in one embodiment a therapeutic combination is provided comprising a first agent and a second agent, wherein the first agent comprises a HDAC
inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand.
[0027] In another embodiment, a co-therapy method for improving cardiovascular performance is provided comprising administering to a subject a first amount of a first agent comprising a HDAC inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
[0028] In yet another embodiment, a co-therapy method for treating cardiovascular diseases is provided comprising administering to a subject a first amount of a first agent comprising a HDAC inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
[0029] The co-therapy method can have one or more of a number of objectives and results, including without limitation to increase the efficacy, decrease the side effects, or enhance the onset of action of the first agent or the second agent, for example.
[0030] As discussed above, the first agent comprises a HDAC inhibiting agent, wherein the HDAC inhibiting agent comprises an HDAC inhibitor (i.e., the HDAC
inhibiting agent comprises one or more independently selected HDAC
inhibitors). An HDAC inhibitor can be an HDAC inhibiting compound or a derivative thereof (e.g., a salt, solvate, hydrate, or prodrug of the HDAC inhibiting compound). Depending on the particular HDAC inhibiting compound, a salt of the compound may be advantageous due to one or more of the salt's physical properties, for example, enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or oil.
Preferably the salt of the HDAC inhibiting compound is a pharmaceutically-acceptable salt.
[0031] In some embodiments, the HDAC inhibiting agent inhibits HDAC 1. In some embodiments, the HDAC inhibiting agent inhibits HDAC 2. In some embodiments, the HDAC inhibiting agent inhibits HDAC 3. In some embodiments, the HDAC
inhibiting agent inhibits HDAC 4. In some embodiments, the HDAC inhibiting agent inhibits HDAC
IMPROVEMENT AND TREATING CARDIOVASCULAR DISEASE
FIELD OF THE INVENTION
[0001i The present invention generally relates to therapeutic combinations and methods useful for improving cardiovascular performance and treating cardiovascular disease.
BACKGROUND OF THE INVENTION
10002] Histone deacetylases ("HDACs") are histone acetyltransferases which transfer an acetyl group to histones thereby playing a role in regulation of gene expression. At present, there are eleven known vertebrate HDACs: HDAC1 through HDAC11. HDAC1, HDAC2, HDAC3, HDAC8, and HDAC11 are class I HDACs. The class I HDACs are ubiquitously expressed, predominantly nuclear, and are believed to function mainly as transcriptional co-repressors. HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10 are class II HDACs. The class II HDACs are tissue specific, suggesting that they may have distinct functions in cellular differentiation and developmental processes. A variety of HDAC inhibitors have been identified.
See, for example, Moradeli et al., Histone Deacetylase Inhibitors: Latest Developments, Trends, and Prospects, CURR MED CHEM: ANTI-CANCER AGENTS 5(5):529-560 (2005).
[0003] Nuclear hormone receptors are ligand-activated transcription factors that regulate gene expression by interacting with specific DNA sequences upstream of their target genes. As early as 1968 a two-step mechanism of action was proposed for these receptors based upon the observation of an inactive and an active state of the receptors.
The first step involves activation through binding of the hormone; the second step consists of receptor binding to DNA and regulation of transcription.
[0004] By interacting with their nuclear receptors, hormones regulate a wide variety of physiological functions including metabolism, growth, and cell differentiation. Because disruptions in these functions often cause disease, the study of nuclear hormone receptors and the hormones which bind them are a rapidly developing area of research.
[0005] Thyroid cells produce the thyroid hormones, thyroxine ("T4") and triiodothyronine (73"). Thyroid hormones exert effects on the heart and the cardiovascular system. T3 has been shown to act on the cardiac myocyte via genomic (nuclear) and nongenomic pathways. T3 binds to nuclear thyroid hormone receptors ("TRs") which in turn bind to thyroid hormone response elements in the promoter region of thyroid hormone-responsive genes. In the presence of T3, TRs activate transcription by recruiting coactivator complexes, and in the absence of T3, TRs repress transcription by recruiting corepressor complexes.
100061 The prevalence of cardiovascular diseases, conditions, and adverse effects is increasing in the patient population. Therefore, there is a need for drug therapies useful for improving cardiovascular performance, and treating cardiovascular disease.
[0007] US 6,544,957 identifies the compound 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinofin-2-yl)-hexanoic acid hydroxyamide, termed "scriptaid" as a histone deacetylase inhibitor, and then mentions a composition containing scriptaid and an expression construct encoding a therapeutic polypeptide to increase production of a polypeptide. However, the patent discloses neither a combination of an HDAC
inhibitor and thyroid hormone, nor a use of any combination of agents treating cardiovascular diseases.
[0008] Thyroid hormone (TH) is known to be involved in histone modification.
More specifically, Alan P. Wolffe, Nature (News and Views) Vol. 287, 16-17 (1997), mentions that the presence of TH helps recruitment of histone acetyltransferases to relieve transcriptional repression. However, this publication does not teach a combination comprising a HDAC inhibitor and a thyroid hormone to treat cardiovascular disease.
100091 Mitchell A. Lazar, J. Clin. Invest. 112:497-499 (2003) mentions that TH
induces binding of transcriptional coactivators possessing histone acetyltransferase activity. However, this publication does not teach a combination comprising a HDAC
inhibitor and a thyroid hormone to treat cardiovascular disease.
SUMMARY OF THE INVENTION
100101 There is now provided, a therapeutic combination comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand, and the second agent is present in a sub-optimal dose.
[0011] There is further provided, a co-therapy method for improving cardiovascular performance, comprising administering to an animal a first amount of a first agent comprising a histone deacetylase inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
[0012] There is still further provided, a co-therapy method for treating cardiovascular disease, comprising administering to an animal a first amount of a first agent comprising a histone deacetylase inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Fig. 1 is a graphical representation of the results obtained from the study described in the Example herein.
[0014] Fig. 2 is a graphical representation of the results obtained from the study described in the Example herein.
DETAILED DESCRIPTION OF THE INVENTION
[0015] This detailed description is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This description and its specific examples are intended for purposes of illustration only. This invention, therefore, is not limited to the embodiments described in this patent application, and may be variously modified.
[0016] In various aspects of the invention, a therapeutic combination and method is provided for improving cardiovascular performance, and preventing and/or treating cardiovascular disease.
100171 The methods of this invention are particularly suitable for use with humans, but may be used with other animals, particularly mammals, such as, for example, non-human primates (e.g., monkeys, chimpanzees, etc.), companion animals (e.g., dogs, cats, horses, etc.), farm animals (e.g., goats, sheep, pigs, cattle, etc.), laboratory animals (e.g., mice, rats, etc.), and wild and zoo animals (e.g., wolves, bears, deer, etc.).
[0018] Cardiovascular performance may be improved in a number of ways. For example, cardiovascular performance is improved by preventing and/or alleviating any cardiovascular-associated condition or symptom. Preventing in this context means reducing the risk of, delaying the onset of, and/or keeping a subject from developing the cardiovascular disease state, condition, or symptom thereof.
[0019] Cardiovascular performance may also be improved by enhancing the cardiovascular fitness of healthy subjects. Examples of cardiovascular improvement include, but are not limited to, increasing a maximum rate of oxygen consumption (VO2max), increasing partial pressure of oxygen (P02), and increasing exercise time.
[0020] Improvement of cardiovascular performance further includes the reduction or elimination of risks or adverse events associated with any cardiovascular treatment or regime.
[0021] Further exemplary improvements of cardiovascular performance include the reduction or alleviation of one or more of the following cardiovascular-associated conditions, symptoms, or adverse events: decreased exercise capacity, severe recurrent headache, decreased blood ejection volume, increased left ventricular end diastolic pressure, increased pulmonary capillary wedge pressure, decreased cardiac output, low cardiac index, increased pulmonary artery pressures, increased left ventricular end systolic and diastolic dimensions, increased left and right ventricular wall stress, increased wall tension, decreased quality of life, disease-related morbidity and mortality, confusion and fatigue, chest pain, dypsnea, irregular heartbeat, and blood in the urine.
[0022] Improvement of cardiovascular performance can be measured in variety of ways known to those skilled in the art. Exemplary methods to measure improvement of cardiovascular performance include, but are not limited to, echocardiogram, electrocardiogram, 6-minute walk test, cardiac index, cardiac output, LVEDP
(left ventricular end diastolic pressure), ejection fraction, PAP (pulmonary arterial pressure), and echo based measurements including cardiac dimension, ventricular filling velocity via Doppler (mitral velocity), decreased dypsnea and pulmonary edema.
[0023] Further, the present invention can be used to treat or alleviate cardiovascular disease states. Treating includes ameliorating and/or eradicating the cardiovascular disease state, condition, or symptom thereof.
[0024] Exemplary cardiovascular disease states or conditions which may be improved include, but are not limited to diastolic heart failure, diastolic dysfunction, cardiac fibrosis, hypertrophy, impaired ventricular relaxation, impaired ventricular filling, pulmonary hypertension, pulmonary edema, shortness of breath, hypertension of all etiologies, acute coronary syndrome (including unstable angina and non-Q wave infarction), myocardial infarction, heart failure, systolic heart failure, stroke, occlusive stroke, hemorrhagic stroke and combinations thereof.
[0025] The term "therapeutic combination" refers to a plurality of agents that, when administered to a subject together or separately, are co-active in bringing therapeutic benefit to the subject. Such administration is referred to as "combination therapy," "co-therapy," "adjunctive therapy" or "add-on therapy." For example, one agent can potentiate or enhance the therapeutic effect of another (i.e. provide a synergistic effect), or reduce an adverse side effect of another, or one or more agents can be effectively administered at a lower dose than when used alone, or can provide greater therapeutic benefit than when used alone, or can complementarily address different aspects, symptoms or etiological factors of a disease or condition.
[0026] As such, in one embodiment a therapeutic combination is provided comprising a first agent and a second agent, wherein the first agent comprises a HDAC
inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand.
[0027] In another embodiment, a co-therapy method for improving cardiovascular performance is provided comprising administering to a subject a first amount of a first agent comprising a HDAC inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
[0028] In yet another embodiment, a co-therapy method for treating cardiovascular diseases is provided comprising administering to a subject a first amount of a first agent comprising a HDAC inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
[0029] The co-therapy method can have one or more of a number of objectives and results, including without limitation to increase the efficacy, decrease the side effects, or enhance the onset of action of the first agent or the second agent, for example.
[0030] As discussed above, the first agent comprises a HDAC inhibiting agent, wherein the HDAC inhibiting agent comprises an HDAC inhibitor (i.e., the HDAC
inhibiting agent comprises one or more independently selected HDAC
inhibitors). An HDAC inhibitor can be an HDAC inhibiting compound or a derivative thereof (e.g., a salt, solvate, hydrate, or prodrug of the HDAC inhibiting compound). Depending on the particular HDAC inhibiting compound, a salt of the compound may be advantageous due to one or more of the salt's physical properties, for example, enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or oil.
Preferably the salt of the HDAC inhibiting compound is a pharmaceutically-acceptable salt.
[0031] In some embodiments, the HDAC inhibiting agent inhibits HDAC 1. In some embodiments, the HDAC inhibiting agent inhibits HDAC 2. In some embodiments, the HDAC inhibiting agent inhibits HDAC 3. In some embodiments, the HDAC
inhibiting agent inhibits HDAC 4. In some embodiments, the HDAC inhibiting agent inhibits HDAC
5. In some embodiments, the HDAC inhibiting agent inhibits HDAC 6. In some embodiments, the HDAC inhibiting agent inhibits HDAC 7. In some embodiments, the HDAC inhibiting agent inhibits HDAC 8. In some embodiments, the HDAC
inhibiting agent inhibits HDAC 9. In some embodiments, the HDAC inhibiting agent inhibits HDAC
10. In some embodiments, the HDAC inhibiting agent inhibits HDAC 11.
[0032] In some embodiments, the HDAC inhibiting agent inhibits two or more of HDAC 1, HDAC 2, HDAC 3, HDAC 4, HDAC 5, HDAC 6, HDAC 7, HDAC 8, HDAC 9, HDAC 10, and HDAC 11. In some such embodiments, the HDAC inhibiting agent inhibits two or more class I HDACs (e.g., HDAC 1, HDAC 2, HDAC 3, HDAC 8, or HDAC
11). In other such embodiments, the HDAC inhibiting agent inhibits two or more class 11 HDACs (e.g., HDAC 4, HDAC 5, HDAC 7, HDAC 9, or HDAC 10). In further such embodiments, the HDAC inhibiting agent inhibits one or more class I HDACs and one or more class II HDACs.
[0033] In some embodiments, the HDAC inhibiting agent comprises a class I HDAC
inhibitor (i.e., the HDAC inhibiting agent comprises one or more independently selected class I HDAC inhibitors). A class I HDAC inhibitor is an inhibitor that inhibits one or more class I HDACs (e.g., HDAC 1, HDAC 2, HDAC 3, HDAC 8, or HDAC 11).
[0034] In some embodiments, the HDAC inhibiting agent comprises a class l[
HDAC
inhibitor (i.e., the HDAC inhibiting agent comprises one or more independently selected class 11 HDAC inhibitors). A class ll HDAC inhibitor is an inhibitor that inhibits one or more class II HDACs (e.g., HDAC 4, HDAC 5, HDAC 7, HDAC 9, or HDAC 10).
[0035] In some embodiments, the HDAC inhibiting agent comprises one or more HDAC inhibitors independently selected from the group consisting of class I
HDAC
inhibitors and class II HDAC inhibitors (e.g., the HDAC inhibiting agent comprises one class I HDAC inhibitor, or the HDAC inhibiting agent comprises two class li HDAC
inhibiting agent inhibits HDAC 9. In some embodiments, the HDAC inhibiting agent inhibits HDAC
10. In some embodiments, the HDAC inhibiting agent inhibits HDAC 11.
[0032] In some embodiments, the HDAC inhibiting agent inhibits two or more of HDAC 1, HDAC 2, HDAC 3, HDAC 4, HDAC 5, HDAC 6, HDAC 7, HDAC 8, HDAC 9, HDAC 10, and HDAC 11. In some such embodiments, the HDAC inhibiting agent inhibits two or more class I HDACs (e.g., HDAC 1, HDAC 2, HDAC 3, HDAC 8, or HDAC
11). In other such embodiments, the HDAC inhibiting agent inhibits two or more class 11 HDACs (e.g., HDAC 4, HDAC 5, HDAC 7, HDAC 9, or HDAC 10). In further such embodiments, the HDAC inhibiting agent inhibits one or more class I HDACs and one or more class II HDACs.
[0033] In some embodiments, the HDAC inhibiting agent comprises a class I HDAC
inhibitor (i.e., the HDAC inhibiting agent comprises one or more independently selected class I HDAC inhibitors). A class I HDAC inhibitor is an inhibitor that inhibits one or more class I HDACs (e.g., HDAC 1, HDAC 2, HDAC 3, HDAC 8, or HDAC 11).
[0034] In some embodiments, the HDAC inhibiting agent comprises a class l[
HDAC
inhibitor (i.e., the HDAC inhibiting agent comprises one or more independently selected class 11 HDAC inhibitors). A class ll HDAC inhibitor is an inhibitor that inhibits one or more class II HDACs (e.g., HDAC 4, HDAC 5, HDAC 7, HDAC 9, or HDAC 10).
[0035] In some embodiments, the HDAC inhibiting agent comprises one or more HDAC inhibitors independently selected from the group consisting of class I
HDAC
inhibitors and class II HDAC inhibitors (e.g., the HDAC inhibiting agent comprises one class I HDAC inhibitor, or the HDAC inhibiting agent comprises two class li HDAC
inhibitors, or the HDAC inhibiting agent comprises one or more class I HDAC
inhibitors and one or more class II HDAC inhibitors).
[0036] In some embodiments, the HDAC inhibiting agent comprises one or more HDAC inhibitors independently selected from the group consisting of HDAC 1 inhibitors, HDAC 2 inhibitors, HDAC 3 inhibitors, HDAC 4 inhibitors, HDAC 5 inhibitors, inhibitors, HDAC 7 inhibitors, HDAC 8 inhibitors, HDAC 9 inhibitors, HDAC 10 inhibitors, and HDAC 11 inhibitors.
[00371 In some embodiments, the HDAC inhibiting agent comprises an HDAC 1 inhibitor (i.e., the HDAC inhibiting agent comprises one or more HDAC 1 inhibitors). In some embodiments, the HDAC inhibiting agent comprises an HDAC 2 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 3 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 4 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 5 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 6 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 7 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 8 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 9 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 10 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 11 inhibitor.
[0038] In some embodiments of the methods of prevention and treatment, the HDAC
inhibiting agent comprises a hydroxamic acid HDAC inhibitor (i.e., the HDAC
inhibiting agent comprises one or more hydroxamic acid HDAC inhibitors and, optionally, one or more additional HDAC inhibitors). Hydroxamic acid HDAC inhibitors suitable for the use with the invention include, for example:
0 H O\~ ,O
N N,OH I \ \ ON o H
Scriptaid JNJ-16241199 INI / N, OH
H H
OH
H ~ N ;~ N, N S
N OH O O p ~ SK-7041 0 PXD 101 HCI O O
H
\ \ N ~ \ N N, OH
H H H
H2N N`OH SAHA 0 / \ I \ H.OH
F NHOH N N Trichostatin A
I O , k \ \ \ \ N-OH
N N H
H \ I / N\ CG-1521 ~ OH
O
H
\ I \ I / N. ~N
H
N OH O s H O NH O O` N,OH
O H
N HN N,OH
N.OH I \
O /
, And O o SY
HO / N
Tubacin [0039] In some embodiments, the HDAC inhibiting agent comprises an aniline amide HDAC inhibitor (i.e., the HDAC inhibiting agent comprises one or more aniline amide HDAC inhibitors and, optionally, one or more additional HDAC inhibitors).
Aniline amide HDAC inhibitors suitable for the methods of prevention and treatment of this invention include, for example:
inhibitors and one or more class II HDAC inhibitors).
[0036] In some embodiments, the HDAC inhibiting agent comprises one or more HDAC inhibitors independently selected from the group consisting of HDAC 1 inhibitors, HDAC 2 inhibitors, HDAC 3 inhibitors, HDAC 4 inhibitors, HDAC 5 inhibitors, inhibitors, HDAC 7 inhibitors, HDAC 8 inhibitors, HDAC 9 inhibitors, HDAC 10 inhibitors, and HDAC 11 inhibitors.
[00371 In some embodiments, the HDAC inhibiting agent comprises an HDAC 1 inhibitor (i.e., the HDAC inhibiting agent comprises one or more HDAC 1 inhibitors). In some embodiments, the HDAC inhibiting agent comprises an HDAC 2 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 3 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 4 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 5 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 6 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 7 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 8 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 9 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 10 inhibitor. In some embodiments, the HDAC inhibiting agent comprises an HDAC 11 inhibitor.
[0038] In some embodiments of the methods of prevention and treatment, the HDAC
inhibiting agent comprises a hydroxamic acid HDAC inhibitor (i.e., the HDAC
inhibiting agent comprises one or more hydroxamic acid HDAC inhibitors and, optionally, one or more additional HDAC inhibitors). Hydroxamic acid HDAC inhibitors suitable for the use with the invention include, for example:
0 H O\~ ,O
N N,OH I \ \ ON o H
Scriptaid JNJ-16241199 INI / N, OH
H H
OH
H ~ N ;~ N, N S
N OH O O p ~ SK-7041 0 PXD 101 HCI O O
H
\ \ N ~ \ N N, OH
H H H
H2N N`OH SAHA 0 / \ I \ H.OH
F NHOH N N Trichostatin A
I O , k \ \ \ \ N-OH
N N H
H \ I / N\ CG-1521 ~ OH
O
H
\ I \ I / N. ~N
H
N OH O s H O NH O O` N,OH
O H
N HN N,OH
N.OH I \
O /
, And O o SY
HO / N
Tubacin [0039] In some embodiments, the HDAC inhibiting agent comprises an aniline amide HDAC inhibitor (i.e., the HDAC inhibiting agent comprises one or more aniline amide HDAC inhibitors and, optionally, one or more additional HDAC inhibitors).
Aniline amide HDAC inhibitors suitable for the methods of prevention and treatment of this invention include, for example:
o o N / N O~ N
N N
HH NH, MGCD0103 and MS-275 HNv~
~ /
[0040J In some embodiments, the HDAC inhibiting agent comprises a ketone HDAC
inhibitor (i.e., the HDAC inhibiting agent comprises one or more ketone HDAC
inhibitors and, optionally, one or more additional HDAC inhibitors). Ketone HDAC
inhibitors suitable for the methods of prevention and treatment of this invention include, for example:
H I/ \
I/ \ O 0 O N~ O CF3 O
S N N~
SH
O
O
/ \ 0 0 / O OH / O
0 O , / \ 0 0 QtDo o l N
N
And N'N
N N
HH NH, MGCD0103 and MS-275 HNv~
~ /
[0040J In some embodiments, the HDAC inhibiting agent comprises a ketone HDAC
inhibitor (i.e., the HDAC inhibiting agent comprises one or more ketone HDAC
inhibitors and, optionally, one or more additional HDAC inhibitors). Ketone HDAC
inhibitors suitable for the methods of prevention and treatment of this invention include, for example:
H I/ \
I/ \ O 0 O N~ O CF3 O
S N N~
SH
O
O
/ \ 0 0 / O OH / O
0 O , / \ 0 0 QtDo o l N
N
And N'N
[0041] In some embodiments, the HDAC inhibiting agent comprises a fatty acid HDAC inhibitor (i.e., the HDAC inhibiting agent comprises one or more fatty acid HDAC
inhibitors and, optionally, one or more additional HDAC inhibitors). Fatty acid HDAC
inhibitors suitable for the methods of prevention and treatment of this invention include, for example:
~\COOH f ~ COOH
"'acooH , and 100421 In some embodiments, the HDAC inhibiting agent comprises one or more HDAC inhibitors independently selected from the group consisting of hydroxamic acid HDAC inhibitors, aniline amide HDAC inhibitors, ketone HDAC inhibitors, and fatty acid inhibitors.
[0043] In some embodiments, the HDAC inhibiting agent comprises one or more inhibitors discussed in Moradeli et al., Histone Deacetylase Inhibitors:
Latest Developments, Trends, and Prospects, CURR MED CHEM: ANTI-CANCER AGENTS
5(5):529-560 (2005).
[0044] As discussed above, the second agent comprises at least one nuclear hormone receptor ligand. Exemplary nuclear hormone receptor ligands include thyroid hormone, DITPA, GC-1, vitamin D, all-trans-retinoic acid, 9-cis-retinoic acid, and including small molecule hormone mimetics. In a particular embodiment, the second agent comprises at least one thyroid hormone. And in yet another embodiment, the second agent comprises T3.
[0045] In some embodiments, the first agent inhibits one or more of HDAC 1, HDAC
2, HDAC 3, HDAC 4, HDAC 5, HDAC 6, HDAC 7, HDAC 8, HDAC 9, HDAC 10, and HDAC 11, and the second agent comprises a thyroid hormone.
[0046] In some embodiments, the first agent inhibits one or more of HDAC 1, HDAC
2, HDAC 3, HDAC 4, HDAC 5, HDAC 6, HDAC 7, HDAC 8, HDAC 9, HDAC 10, and HDAC 11, and the second agent comprises T3.
[0047] It should be understood that the second agent of this invention may be used with any combination of the first agent as previously described herein.
[0048] In some embodiments, the second agent is present in a sub-optimal dose, where sub-optimal dose implies a dose of the second agent insufficient to produce modulate cardiac performance, chamber size or pressures.
[0049] In some embodiments, the first agent is administered at a dose of about 0.01 to about 100 mg/day and the second agent is administered at a single dose of about 0.1 to about 100 pg/day.
100501 In another embodiment, the combination of the present invention results in the modification of a-myosin heavy chain (MHC) transcription. In particular, the combination results in an increase in both a-MHC transcription and protein expression.
[0051] In some embodiments, a therapeutic agent used in the combinations and methods of this invention is administered as part of a pharmaceutical composition (or medicament) that further comprises one or more pharmaceutically-acceptable carriers, diluents, wetting or suspending agents, vehicles, and/or adjuvants (the carriers, diluents, wetting or suspending agents, vehicles, and adjuvants are sometimes being collectively referred to in this patent application as "carrier materials"); and/or other active ingredients.
100521 Co-administration of a first and a second agent, as in the co-therapy method of the invention, comprises administration of the agents in amounts sufficient to achieve or maintain therapeutically effective concentrations, e.g., plasma concentrations, in the subject in need thereof. Co-administration can comprise one or both of simultaneous and subsequent (i.e., sequential) administration. Simultaneous administration can comprise administration of the agents as a single composition or as different compositions (see below) "at the same time" within a treatment period.
Sequential administration can comprise administration of the agents at different times, for example "at intervals" within a treatment period.
[0053] Administration "at the same time" includes administration of the first and second agents literally "at the same time," but also includes administration directly one after the other, in any order. Administration "at intervals" includes administration of the first agent and the second agent at different times, separated for example by an interval of about 1 h, about 6 h, about 12 h, about 1 day, or about 1 month at the maximum.
[0054] The first agent and the second agent may be formulated in one pharmaceutical preparation (single dose form) for administration at the same time or may be formulated in two distinct preparations (separate dose forms) for administration at the same time or sequentially.
[0055] The two distinct preparations in the separate dose forms may be administered by the same route or by different routes. The first and second agents of the present invention may be administered orally, but the invention is not limited to any route of administration, so long as the route selected results in effective delivery of the drug so that the stated benefits are obtainable. Thus administration of the combination can illustratively be parenteral (e.g., intravenous, intraperitoneal, subcutaneous or intradermal), transdermal, transmucosal (e.g., buccal, sublingual or intranasal), intraocular, intrapulmonary (e.g., by inhalation), rectal, or any combination thereof. If the combination is delivered orally, any suitable orally deliverable dosage form can be used, including without limitation tablets, capsules (solid- or liquid-filled), powders, granules, syrups and other liquids, etc.
[0056] Separate dose forms can optionally be co-packaged, for example in a single container or in a plurality of containers within a single outer package, or co-presented in separate packaging ("common presentation"). As an example of co-packaging or common presentation, a kit is contemplated comprising, in separate containers, the first agent and the second agent. In another example, the first agent and the second agent are separately packaged and available for sale independently of one another, but are co-marketed or co-promoted for use according to the invention. The separate dose forms may also be presented to a subject separately and independently, for use according to the invention.
100571 Depending on the dosage forms, which may be identical or different, e.g., fast release dosage forms, controlled release dosage forms or depot forms, the first agent and the second agent may be administered on the same or on different schedules, for example on a daily, weekly or monthly basis. Therefore, the administration interval in a co-therapy method of the invention may depend on the administration schedules or on the dosage forms.
EXAMPLE
[0058] The following example is merely illustrative, and not limiting to the remainder of this disclosure in any way.
[0059] Male S.D. rats (7 wks old) were rendered hypothyroid by being fed PTU
diet (n =
48; iodine deficient, 0.15% propylthiouracil) or normal chow (n = 8) for 2 weeks. PTU fed rats were then separated into weight-matched groups the day prior to inception of the study, and treated for 4 days with vehicle (0.05 mL/100g BW i.p.; 20%
Cremophor EL;
20% ethanol; 60% H20) or T3 (3 pg/kg) and scriptaid (1.5, 15 mg/kg) or its vehicle (100%
DMSO; 0.04 mL/100g BW i.p.). Because of differential pharmacodynamics of T3 and scriptaid, each animal received T3 or its vehicle at least 3 hours prior to receiving scriptaid or its vehicle. Following 4 days of treatment, core temperature, systemic hemodynamics, and cardiac performance data were collected under isoflurane anesthesia using the Millar direct catheter system no less two hours following scriptaid administration. At the conclusion of the experiment the animals were sacrificed, and blood and tissues collected for morphological and biochemical analysis.
Hypothyroid rats have impaired systolic and diastolic cardiac performance relative to euthyroid control rats, while scriptaid alone exerted no effects on either systolic or diastolic cardiac performance. Exogenous T3 increased both maximal positive and negative dP/dt (See Fig. 1); indices of systolic and diastolic performance, respectively while tau (an index of myocardial relaxation) was also improved (See Fig. 2). Coadministration of scriptaid significantly enhanced the effects of T3 treatment on each index (maximal +/-dP/dt, tau) of cardiac performance, indicating that low doses of HDAC inhibitors potentiate the effects of nuclear hormone receptor ligands.
inhibitors and, optionally, one or more additional HDAC inhibitors). Fatty acid HDAC
inhibitors suitable for the methods of prevention and treatment of this invention include, for example:
~\COOH f ~ COOH
"'acooH , and 100421 In some embodiments, the HDAC inhibiting agent comprises one or more HDAC inhibitors independently selected from the group consisting of hydroxamic acid HDAC inhibitors, aniline amide HDAC inhibitors, ketone HDAC inhibitors, and fatty acid inhibitors.
[0043] In some embodiments, the HDAC inhibiting agent comprises one or more inhibitors discussed in Moradeli et al., Histone Deacetylase Inhibitors:
Latest Developments, Trends, and Prospects, CURR MED CHEM: ANTI-CANCER AGENTS
5(5):529-560 (2005).
[0044] As discussed above, the second agent comprises at least one nuclear hormone receptor ligand. Exemplary nuclear hormone receptor ligands include thyroid hormone, DITPA, GC-1, vitamin D, all-trans-retinoic acid, 9-cis-retinoic acid, and including small molecule hormone mimetics. In a particular embodiment, the second agent comprises at least one thyroid hormone. And in yet another embodiment, the second agent comprises T3.
[0045] In some embodiments, the first agent inhibits one or more of HDAC 1, HDAC
2, HDAC 3, HDAC 4, HDAC 5, HDAC 6, HDAC 7, HDAC 8, HDAC 9, HDAC 10, and HDAC 11, and the second agent comprises a thyroid hormone.
[0046] In some embodiments, the first agent inhibits one or more of HDAC 1, HDAC
2, HDAC 3, HDAC 4, HDAC 5, HDAC 6, HDAC 7, HDAC 8, HDAC 9, HDAC 10, and HDAC 11, and the second agent comprises T3.
[0047] It should be understood that the second agent of this invention may be used with any combination of the first agent as previously described herein.
[0048] In some embodiments, the second agent is present in a sub-optimal dose, where sub-optimal dose implies a dose of the second agent insufficient to produce modulate cardiac performance, chamber size or pressures.
[0049] In some embodiments, the first agent is administered at a dose of about 0.01 to about 100 mg/day and the second agent is administered at a single dose of about 0.1 to about 100 pg/day.
100501 In another embodiment, the combination of the present invention results in the modification of a-myosin heavy chain (MHC) transcription. In particular, the combination results in an increase in both a-MHC transcription and protein expression.
[0051] In some embodiments, a therapeutic agent used in the combinations and methods of this invention is administered as part of a pharmaceutical composition (or medicament) that further comprises one or more pharmaceutically-acceptable carriers, diluents, wetting or suspending agents, vehicles, and/or adjuvants (the carriers, diluents, wetting or suspending agents, vehicles, and adjuvants are sometimes being collectively referred to in this patent application as "carrier materials"); and/or other active ingredients.
100521 Co-administration of a first and a second agent, as in the co-therapy method of the invention, comprises administration of the agents in amounts sufficient to achieve or maintain therapeutically effective concentrations, e.g., plasma concentrations, in the subject in need thereof. Co-administration can comprise one or both of simultaneous and subsequent (i.e., sequential) administration. Simultaneous administration can comprise administration of the agents as a single composition or as different compositions (see below) "at the same time" within a treatment period.
Sequential administration can comprise administration of the agents at different times, for example "at intervals" within a treatment period.
[0053] Administration "at the same time" includes administration of the first and second agents literally "at the same time," but also includes administration directly one after the other, in any order. Administration "at intervals" includes administration of the first agent and the second agent at different times, separated for example by an interval of about 1 h, about 6 h, about 12 h, about 1 day, or about 1 month at the maximum.
[0054] The first agent and the second agent may be formulated in one pharmaceutical preparation (single dose form) for administration at the same time or may be formulated in two distinct preparations (separate dose forms) for administration at the same time or sequentially.
[0055] The two distinct preparations in the separate dose forms may be administered by the same route or by different routes. The first and second agents of the present invention may be administered orally, but the invention is not limited to any route of administration, so long as the route selected results in effective delivery of the drug so that the stated benefits are obtainable. Thus administration of the combination can illustratively be parenteral (e.g., intravenous, intraperitoneal, subcutaneous or intradermal), transdermal, transmucosal (e.g., buccal, sublingual or intranasal), intraocular, intrapulmonary (e.g., by inhalation), rectal, or any combination thereof. If the combination is delivered orally, any suitable orally deliverable dosage form can be used, including without limitation tablets, capsules (solid- or liquid-filled), powders, granules, syrups and other liquids, etc.
[0056] Separate dose forms can optionally be co-packaged, for example in a single container or in a plurality of containers within a single outer package, or co-presented in separate packaging ("common presentation"). As an example of co-packaging or common presentation, a kit is contemplated comprising, in separate containers, the first agent and the second agent. In another example, the first agent and the second agent are separately packaged and available for sale independently of one another, but are co-marketed or co-promoted for use according to the invention. The separate dose forms may also be presented to a subject separately and independently, for use according to the invention.
100571 Depending on the dosage forms, which may be identical or different, e.g., fast release dosage forms, controlled release dosage forms or depot forms, the first agent and the second agent may be administered on the same or on different schedules, for example on a daily, weekly or monthly basis. Therefore, the administration interval in a co-therapy method of the invention may depend on the administration schedules or on the dosage forms.
EXAMPLE
[0058] The following example is merely illustrative, and not limiting to the remainder of this disclosure in any way.
[0059] Male S.D. rats (7 wks old) were rendered hypothyroid by being fed PTU
diet (n =
48; iodine deficient, 0.15% propylthiouracil) or normal chow (n = 8) for 2 weeks. PTU fed rats were then separated into weight-matched groups the day prior to inception of the study, and treated for 4 days with vehicle (0.05 mL/100g BW i.p.; 20%
Cremophor EL;
20% ethanol; 60% H20) or T3 (3 pg/kg) and scriptaid (1.5, 15 mg/kg) or its vehicle (100%
DMSO; 0.04 mL/100g BW i.p.). Because of differential pharmacodynamics of T3 and scriptaid, each animal received T3 or its vehicle at least 3 hours prior to receiving scriptaid or its vehicle. Following 4 days of treatment, core temperature, systemic hemodynamics, and cardiac performance data were collected under isoflurane anesthesia using the Millar direct catheter system no less two hours following scriptaid administration. At the conclusion of the experiment the animals were sacrificed, and blood and tissues collected for morphological and biochemical analysis.
Hypothyroid rats have impaired systolic and diastolic cardiac performance relative to euthyroid control rats, while scriptaid alone exerted no effects on either systolic or diastolic cardiac performance. Exogenous T3 increased both maximal positive and negative dP/dt (See Fig. 1); indices of systolic and diastolic performance, respectively while tau (an index of myocardial relaxation) was also improved (See Fig. 2). Coadministration of scriptaid significantly enhanced the effects of T3 treatment on each index (maximal +/-dP/dt, tau) of cardiac performance, indicating that low doses of HDAC inhibitors potentiate the effects of nuclear hormone receptor ligands.
Claims (15)
1. A therapeutic combination comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand, and the second agent is present in a sub-optimal dose.
2. The combination of Claim 1, wherein the second agent comprises at least one thyroid hormone.
3. The combination of Claim 2, wherein the at least one thyroid hormone is tri-iodothyronine.
4. The combination of Claim 1, wherein the first agent comprises one or more histone deacetylase inhibitors independently selected from the group consisting of histone deacetylase 1 inhibitors, histone deacetylase 2 inhibitors, histone deacetylase 3 inhibitors, histone deacetylase 4 inhibitors, histone deacetylase 5 inhibitors, histone deacetylase 6 inhibitors, histone deacetylase 7 inhibitors, histone deacetylase 8 inhibitors, histone deacetylase 9 inhibitors, histone deacetylase 10 inhibitors, and histone deacetylase 11 inhibitors.
5. The combination of Claim 1, wherein the first agent comprises one or more histone deacetylase inhibitors independently selected from the group consisting of:
6. The combination of Claim 5, wherein the second agent comprises tri-iodothyronine.
7. A co-therapy method for improving cardiovascular performance or treating cardiovascular disease, comprising administering to a human a first amount of a first agent comprising a histone deacetylase inhibiting agent and a second amount of a second agent comprising at least one nuclear hormone receptor ligand, wherein the first amount and second amount together provide a therapeutically effective combination of the first agent and second agent.
8. The method of Claim 7, wherein the second agent comprises at least one thyroid hormone, and the amount of the second agent is a sub-optimal dose,
9. The method of Claim 8, wherein the at least one thyroid hormone is tri-iodothyronine.
10. The method of Claim 7, wherein the first agent comprises one or more histone deacetylase inhibitors independently selected from the group consisting of histone deacetylase 1 inhibitors, histone deacetylase 2 inhibitors, histone deacetylase 3 inhibitors, histone deacetylase 4 inhibitors, histone deacetylase 5 inhibitors, histone deacetylase 6 inhibitors, histone deacetylase 7 inhibitors, histone deacetylase 8 inhibitors, histone deacetylase 9 inhibitors, histone deacetylase 10 inhibitors, and histone deacetylase 11 inhibitors.
11.The method of Claim 7, wherein the first agent comprises one or more histone deacetylase inhibitors independently selected from the group consisting of:
12.The method of Claim 11, wherein the second agent comprises tri-iodothyronine and the amount of the second agent is a sub-optimal dose.
13.The method of Claim 7, wherein the cardiovascular disease treated is selected from the group consisting of diastolic heart failure, diastolic dysfunction, cardiac fibrosis, hypertrophy, impaired ventricular relaxation, impaired ventricular filling, pulmonary hypertension, pulmonary edema, shortness of breath, hypertension of all etiologies, acute coronary syndrome including unstable angina and non-Q wave infarction, myocardial infarction, heart failure, systolic heart failure, stroke, occlusive stroke, and hemorrhagic stroke.
14.The method of Claim 7, wherein the administration of the first agent and the second agent results in modification of .alpha.-myosin heavy chain (MHC) transcription.
15.The method of Claim 7, wherein the first agent is administered at a dose of about 0.01 to about 100 mg/day and the second agent is administered at a single dose of about 0.1 to about 100 µg/day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002639336A CA2639336A1 (en) | 2008-09-05 | 2008-09-05 | Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002639336A CA2639336A1 (en) | 2008-09-05 | 2008-09-05 | Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2639336A1 true CA2639336A1 (en) | 2010-03-05 |
Family
ID=41808964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002639336A Abandoned CA2639336A1 (en) | 2008-09-05 | 2008-09-05 | Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2639336A1 (en) |
-
2008
- 2008-09-05 CA CA002639336A patent/CA2639336A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090076021A1 (en) | Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease | |
US10881629B2 (en) | Methods and compositions for increasing the anaerobic working capacity in tissues | |
JP2022020624A (en) | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling | |
US20080119557A1 (en) | Combination Of Organic Compounds | |
US20080261958A1 (en) | Combination of Organic Compounds | |
EA022166B1 (en) | Synthetic triterpenoids and methods of use in the treatment of disease | |
MX2007000142A (en) | Methods and reagents for the treatment of metabolic disorders. | |
TW200836715A (en) | Novel composition for treating metabolic syndrome | |
JP2006117691A (en) | Use of lipoxin analogs to promote cell defense against gram- negative infections | |
US20150258047A1 (en) | Therapeutic Compounds | |
US20210379043A1 (en) | Combination treatment of liver disorders | |
KR20130048281A (en) | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure | |
AU784493B2 (en) | Endogenous nitric oxide synthesis under conditions of low oxygen tension | |
JP5308350B2 (en) | Combination therapy of lower urinary tract dysfunction using α2δ ligand and NSAID | |
JP4874489B2 (en) | Use of COMT inhibitors as analgesics | |
JP4848367B2 (en) | Treatment of seizures using ICE inhibitors | |
US20230241071A1 (en) | Combination treatment of liver disorders | |
CA2639336A1 (en) | Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease | |
EP3703670A1 (en) | Compositions and methods for treating septic cardiomyopathy | |
KR20100016512A (en) | Use of iron chelator for the treatment of myocardial infarction | |
TWI322687B (en) | Combination of antidiabetic drugs | |
WO2008006819A2 (en) | Use of ppar-alpha agonists to treat skeletal muscle wasting disorders | |
EP3834888A2 (en) | Agents for treatment of alcohol use disorder | |
WO2011103563A1 (en) | Methods and compositions for inhibiting and preventing the growth of malignant mast cells | |
FR2551974A1 (en) | PREPARATION OF DOBUTAMINE FOR ORAL ADMINISTRATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20120905 |